- Home
- KLTOW vs KFRC Comparison
KLTOW vs KFRC Comparison
Compare KLTOW & KFRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTOW
- KFRC
- Stock Information
- Founded
- KLTOW N/A
- KFRC 1962
- Country
- KLTOW United States
- KFRC United States
- Employees
- KLTOW 3
- KFRC N/A
- Industry
- KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
- KFRC Professional Services
- Sector
- KLTOW Health Care
- KFRC Consumer Discretionary
- Exchange
- KLTOW Nasdaq
- KFRC Nasdaq
- Market Cap
- KLTOW N/A
- KFRC N/A
- IPO Year
- KLTOW 2022
- KFRC 1995
- Fundamental
- Price
- KLTOW $0.02
- KFRC $39.25
- Analyst Decision
- KLTOW
- KFRC Buy
- Analyst Count
- KLTOW 0
- KFRC 3
- Target Price
- KLTOW N/A
- KFRC $53.67
- AVG Volume (30 Days)
- KLTOW N/A
- KFRC 204.7K
- Earning Date
- KLTOW N/A
- KFRC 04-28-2025
- Dividend Yield
- KLTOW N/A
- KFRC 3.98%
- EPS Growth
- KLTOW N/A
- KFRC N/A
- EPS
- KLTOW N/A
- KFRC 2.56
- Revenue
- KLTOW N/A
- KFRC $1,383,447,000.00
- Revenue This Year
- KLTOW N/A
- KFRC N/A
- Revenue Next Year
- KLTOW N/A
- KFRC $6.34
- P/E Ratio
- KLTOW N/A
- KFRC $15.36
- Revenue Growth
- KLTOW N/A
- KFRC N/A
- 52 Week Low
- KLTOW N/A
- KFRC $35.50
- 52 Week High
- KLTOW N/A
- KFRC $71.48
- Technical
- Relative Strength Index (RSI)
- KLTOW N/A
- KFRC 37.87
- Support Level
- KLTOW N/A
- KFRC $36.95
- Resistance Level
- KLTOW N/A
- KFRC $39.28
- Average True Range (ATR)
- KLTOW 0.00
- KFRC 1.63
- MACD
- KLTOW 0.00
- KFRC -0.03
- Stochastic Oscillator
- KLTOW 0.00
- KFRC 33.75
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.